This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DiGiuseppe, J. A. Articles by van Mansfeld, A. D. Search for Related Content PubMed PubMed Citation Articles by DiGiuseppe, J. A. Articles by van Mansfeld, A. D.

American Journal of Pathology, Vol 144, 889-895, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma

JA DiGiuseppe, RH Hruban, GJ Offerhaus, MJ Clement, FM van den Berg, JL Cameron and AD van Mansfeld
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Mutations in the K-ras oncogene and in the p53 tumor suppressor gene are commonly identified in sporadic cases of pancreatic adenocarcinoma. Although these genes might serve as useful markers for early diagnosis of pancreatic carcinoma in patients at risk for the development of this disease, familial pancreatic carcinomas have not been studied for these mutations. We recently had the opportunity to examine a pancreas prophylactically removed from a patient with a strong family history of pancreatic carcinoma. This gave us the unique opportunity to study the early events in the development of familial adenocarcinoma of the pancreas. Histopathological examination of the pancreas revealed multifocal papillary and nonpapillary mucinous duct hyperplasia. Seven of these foci were microdissected and analyzed for K-ras and p53 mutations. The K-ras mutations were detected by combined mutant- enriched polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one. In contrast, these lesions did not harbor detectable p53 mutations as determined by denaturing gradient gel electrophoresis of exons 5 to 8, nor was there overexpression of the p53 protein as determined by immunohistochemistry. These findings suggest that mutations in K-ras represent an early event in the pathogenesis of pancreatic carcinoma. In addition, monitoring of patients with a strong family history of pancreatic carcinoma for K-ras mutations may identify patients at risk for the development of invasive carcinoma.

This article has been cited by other articles:

				C Brockschmidt, H Hirner, N Huber, T Eismann, A Hillenbrand, G Giamas, B Radunsky, O Ammerpohl, B Bohm, D Henne-Bruns, et al. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo Gut, June 1, 2008; 57(6): 799 - 806. [Abstract] [Full Text] [PDF]

				M. Li, U. Bharadwaj, R. Zhang, S. Zhang, H. Mu, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Mol. Cancer Ther., February 1, 2008; 7(2): 286 - 296. [Abstract] [Full Text] [PDF]

				N. Bardeesy, A. J. Aguirre, G. C. Chu, K.-h. Cheng, L. V. Lopez, A. F. Hezel, B. Feng, C. Brennan, R. Weissleder, U. Mahmood, et al. From the Cover: Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse PNAS, April 11, 2006; 103(15): 5947 - 5952. [Abstract] [Full Text] [PDF]

				S. E. Dowen, T. Crnogorac-Jurcevic, R. Gangeswaran, M. Hansen, J. J. Eloranta, V. Bhakta, T. A. Brentnall, J. Luttges, G. Kloppel, and N. R. Lemoine Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer Am. J. Pathol., January 1, 2005; 166(1): 81 - 92. [Abstract] [Full Text] [PDF]

				W. H. de Vos tot Nederveen Cappel, G. J. A. Offerhaus, M. van Puijenbroek, E. Caspers, N. A. Gruis, F. A. de Snoo, C. B. H. W. Lamers, G. Griffioen, W. Bergman, H. F. A. Vasen, et al. Pancreatic Carcinoma in Carriers of a Specific 19 Base Pair Deletion of CDKN2A/p16 (p16-Leiden) Clin. Cancer Res., September 1, 2003; 9(10): 3598 - 3605. [Abstract] [Full Text] [PDF]

				W. W. J. de Leng, A. M. Westerman, M. A. J. Weterman, F. W. M. de Rooij, H. v. Dekken, A. F. P. M. de Goeij, S. B. Gruber, J. H. P. Wilson, G. J. A. Offerhaus, F. M. Giardiello, et al. Cyclooxygenase 2 Expression and Molecular Alterations in Peutz-Jeghers Hamartomas and Carcinomas Clin. Cancer Res., August 1, 2003; 9(8): 3065 - 3072. [Abstract] [Full Text] [PDF]

				S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero A White Paper: The Product of a Pancreas Cancer Think Tank Cancer Res., June 1, 2001; 61(12): 4923 - 4932. [Full Text] [PDF]

				E. Lopez-Crapez, T. Livache, J. Marchand, and J. Grenier K-ras Mutation Detection by Hybridization to a Polypyrrole DNA Chip Clin. Chem., February 1, 2001; 47(2): 186 - 194. [Abstract] [Full Text] [PDF]

				M M Entius, J J Keller, A M Westerman, B P van Rees, M-L F van Velthuysen, A F P M de Goeij, J H P Wilson, F M Giardiello, and G J A Offerhaus Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome J. Clin. Pathol., February 1, 2001; 54(2): 126 - 131. [Abstract] [Full Text] [PDF]

				R. H. Hruban, M. Goggins, J. Parsons, and S. E. Kern Progression Model for Pancreatic Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2969 - 2972. [Full Text]

				R. H. Hruban, R. E. Wilentz, and S. E. Kern Genetic Progression in the Pancreatic Ducts Am. J. Pathol., June 1, 2000; 156(6): 1821 - 1825. [Abstract] [Full Text] [PDF]

				M. Goggins, R. H. Hruban, and S. E. Kern BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia : Evidence and Implications Am. J. Pathol., May 1, 2000; 156(5): 1767 - 1771. [Abstract] [Full Text] [PDF]

				P. D. J. Sturm, E. A. J. Rauws, R. H. Hruban, E. Caspers, T. B. Ramsoekh, K. Huibregtse, L. A. Noorduyn, and G. J. A. Offerhaus Clinical Value of K-ras Codon 12 Analysis and Endobiliary Brush Cytology for the Diagnosis of Malignant Extrahepatic BileDuct Stenosis Clin. Cancer Res., March 1, 1999; 5(3): 629 - 635. [Abstract] [Full Text] [PDF]

				J. Mora, P. Puig, J. Boadas, E. Urgell, E. Montserrat, E. Lerma, F. Gonzalez-Sastre, F. Lluis, A. Farre, and G. Capella K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits Clin. Chem., November 1, 1998; 44(11): 2243 - 2248. [Abstract] [Full Text] [PDF]